McGhee Julie L, Kickingbird Lauren M, Jarvis James N
Department of Pediatrics, University of Oklahoma College of Medicine, Oklahoma City, OK, USA.
BMC Pediatr. 2004 Jul 9;4:13. doi: 10.1186/1471-2431-4-13.
Antinuclear antibody (ANA) tests are frequently used to screen children for chronic inflammatory diseases such as systemic lupus erythematosus (SLE). However, the diagnostic utility of this test is limited because of the large number of healthy children who have low-titer positive tests. We sought to determine the clinical utility of ANA tests in screening children for rheumatic disease and to determine whether there are specific signs or symptoms that enhance the clinical utility of ANA tests in children.
We undertook a retrospective analysis of 509 new patient referrals. Charts of patients referred because of results of ANA testing were selected for further analysis. Children with JRA, SLE, and other conditions were compared using demographic data, chief complaints at the time of presentation, and ANA titers.
One hundred ten patients were referred because of an ANA test interpreted as positive. Ten patients were subsequently diagnosed with SLE. In addition, we identified one patient with mixed connective tissue disease, and an additional child with idiopathic Raynaud's phenomenon. Eighteen children of the children referred for a positive ANA test had juvenile rheumatoid arthritis (JRA). Another 80 children with positive ANA tests were identified, the majority of whom (n = 39, 49%) had musculoskeletal pain syndromes. Neither the presence nor the titer of ANA served to distinguish children with JRA from children with other musculoskeletal conditions. Children with JRA were readily identified on the basis of the history and physical examination. Children with SLE were therefore compared with children with positive ANA tests who did not have JRA, designated the "comparison group." Non-urticarial rash was more common in children with SLE than in children without chronic inflammatory disease (p = 0.007). Children with SLE were also older (mean +/- sd = 14.2 +/- 2.5 years) than the comparison group (11.0 +/- 3.6 years; p = 0.001). ANA titer was also a significant discriminator between children with SLE and children without chronic inflammatory disease. The median ANA titer in children with SLE was 1: 1,080 compared with 1:160 for other children (p < 0.0001). ANA titers of >/=1,080 had a positive predictive value for SLE of 1.0 while titers of </=1: 360 had a negative predictive value for lupus of 0.84.
Age and ANA titer assist in discriminating children with SLE from children with other conditions. ANA tests are of no diagnostic utility in either making or excluding the diagnosis of JRA.
抗核抗体(ANA)检测常用于筛查儿童慢性炎症性疾病,如系统性红斑狼疮(SLE)。然而,由于大量健康儿童检测结果为低滴度阳性,该检测的诊断效用有限。我们试图确定ANA检测在筛查儿童风湿性疾病中的临床效用,并确定是否有特定体征或症状可增强ANA检测在儿童中的临床效用。
我们对509例新患者转诊病例进行了回顾性分析。选择因ANA检测结果而转诊的患者病历进行进一步分析。使用人口统计学数据、就诊时的主要症状和ANA滴度对患有幼年特发性关节炎(JRA)、SLE和其他疾病的儿童进行比较。
1例患者因ANA检测结果被解释为阳性而转诊。其中10例患者随后被诊断为SLE。此外,我们还确定了1例混合性结缔组织病患者和1例特发性雷诺现象患儿。转诊进行ANA检测的儿童中有18例患有幼年类风湿关节炎(JRA)。另外还发现80例ANA检测呈阳性儿童,其中大多数(n = 39,49%)患有肌肉骨骼疼痛综合征。ANA的存在与否及滴度均无法区分JRA患儿与其他肌肉骨骼疾病患儿。根据病史和体格检查很容易识别出JRA患儿。因此,将SLE患儿与ANA检测呈阳性但无JRA的患儿(指定为“对照组”)进行比较。非荨麻疹性皮疹在SLE患儿中比在无慢性炎症性疾病的患儿中更常见(p = 0.007)。SLE患儿的年龄也比对照组大(平均±标准差 = 14.2±2.5岁)(11.0±3.6岁;p = 0.001)。ANA滴度也是SLE患儿与无慢性炎症性疾病患儿之间的一个重要鉴别指标。SLE患儿的ANA滴度中位数为1:1080,而其他儿童为1:160(p < 0.0001)。ANA滴度≥1:1080对SLE的阳性预测值为1.0,而滴度≤1:360对狼疮的阴性预测值为0.84。
年龄和ANA滴度有助于区分SLE患儿与其他疾病患儿。ANA检测在诊断或排除JRA方面无诊断效用。